OpenAI has acquired Torch, a startup focused on creating a unified medical memory for AI, for about $60 million. The deal aims to centralize patient health data, which is often fragmented across various systems. Torch's CEO, Ilya Abyzov, expressed excitement about integrating their technology with OpenAI's existing health tools.

The FDA is exploring the use of AI, specifically through discussions with OpenAI, to expedite the drug approval process. This initiative, led by the FDA's first AI officer, aims to modernize regulatory reviews, although concerns about AI reliability and proper data training persist.